Revenue Of Leqembi (Preliminary Basis)
06/02/2026 11:03
Feb 6 (Reuters) - Eisai Co Ltd 4523.T: EISAI CO LTD: REVENUE OF LEQEMBI (PRELIMINARY BASIS) EISAI CO LTD: GLOBAL REVENUE (PRE-AUDIT BASIS) OF ANTI-AMYLOID-BETA PROTOFIBRIL ANTIBODY LEQEMBI WAS 61.8 BILLION YEN FOR THE CUMULATIVE PERIOD OF Q3 OF FY2025 Source text: ID:nTSnf8673d Further company coverage: 4523.T (Reporting by Tokyo Newsroom) ((+81345201189;))
Recent news on Eisai
See all newsBiogen tops quarterly estimates on rare-disease drug strength (updated)
Biogen beats third-quarter results on strength in rare disease drugs
Brief: FDA Approves Belzutifan-Lenvatinib Combination for Advanced Renal Cell Carcinoma With A Clear Cell Component
Leqembi Pen (Subcutaneous Formulation Of Leqembi) Approved In Japan
Leqembi (Lecanemab) Subcutaneous Formulation As An Initiation Treatment For Early Alzheimer's Disease Approved In China